Jacobs Journal of Cancer Science and Research

Immunotherapy and Ovarian Cancer

Published on: 2018-10-29


Ovarian cancer is one of the leading causes of death and poses a significant health challenge worldwide. The standard therapy for ovarian cancer involving use of surgery and platinum chemotherapy had led to recurrence among majority of patients. Recent improvement in the understanding of the etiology and molecular characteritics of ovarian cancer has paved the way for exploring the utility of immunotherapy for ovarian cancer. Currently, Avastin (Bevacizumab) is the only US FDA approved immunotherapy to be used in combination with chemotherapy among women who have advanced ovarian cancer. Ongoing and planned clinical trials exploring the potential of various immunotherapy modalities will ultimately demonstrate the clinical utility of this therapeutic strategy. This article focuses on the immunotherapies that may offer therapeutic opportunities in the future.


Ovarian cancer; Bevacizumab; Immunotherapy; Adoptive T-Cell Therapies; Therapeutic Vaccines